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Background: Past attempts at detecting prostate cancer (PCa) cells in voided urine by traditional cytology have
been impeded by undesirably low sensitivities but high specificities. To improve the sensitivities, we evaluate the
feasibility and clinical utility of photodynamic diagnosis (PDD) of prostate cancer by using 5-aminolevulinic acid
(5-ALA) to examine shed prostate cancer cells in voided urine samples.
Methods: One hundred thirty-eight patients with an abnormal digital rectal exam (DRE) and/or abnormal
prostate-specific antigen (PSA) levels were recruited between April 2009 and December 2010. Voided urine
specimens were collected before prostate biopsy. Urine specimens were treated with 5-ALA and imaged by
fluorescence microscopy and reported as protoporphyrin IX (PPIX) positive (presence of cells demonstrating
simultaneous PPIX fluorescence) or PPIX negative (lack of cells demonstrating fluorescence).
Results: Of the 138 patients, PCa was detected on needle biopsy in 81 patients (58.7%); of these 81 patients with
PCa, 60 were PPIX-positive (sensitivity: 74.1%). Although 57 patients did not harbor PCa by conventional diagnostic
procedures, 17 of these at-risk patients were found to be PPIX-positive (specificity: 70.2%). PPIX–PDD was more
sensitive compared with DRE and transrectal ultrasound and more specific compared with PSA and PSA density.
The incidence of PPIX–PDD positivity did not increase with increasing total PSA levels, tumor stage or Gleason
score.
Conclusions: To our knowledge, this is the first successful demonstration of PPIX in urine sediments treated with
5-ALA used to detect PCa in a noninvasive yet highly sensitive manner. However, further studies are warranted to
determine the role of PPIX–PPD for PCa detection.
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Detection of prostate cancer (PCa) primarily relies on an
abnormal digital rectal examination (DRE) and/or in-
creased prostate specific antigen (PSA) levels. Despite its
widespread use, PSA has marginal specificity, and 65%–
70% males with elevated PSA levels within 4–10 ng/ml
generally reveal a negative biopsy result [1]. Therefore,
PSA is not the ideal screening tool for prostate cancer.
To improve PSA specificity, various analyses have been
introduced such as PSA density, PSA velocity, and free/* Correspondence: kiyokun@naramed-u.ac.jp
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unless otherwise stated.total PSA; however, these methods have not appreciably
improved the cancer detection rates. In addition, be-
cause of sampling errors or sampling inefficiencies as-
sociated with transrectal ultrasound-guided biopsy of
the prostate, some PCa may be missed (false negative).
Therefore, there is a clear need for clinically useful bio-
markers that would allow earlier detection of clinically
significant PCa. For this reason, there is currently con-
siderable interest in novel noninvasive biomarkers (e.g.,
urine- or serum-based assays) to assist in the diagnosis of
PCa [2]. Nevertheless, to date, no routinely used tumor
biomarker has replaced PSA.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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http://www.biomedcentral.com/1471-2490/14/59Upon prostatic massage, prostate cells (including PCa
cells) may be dislodged and displaced into the urethra
and urine. However, unlike bladder cancer, wherein voi-
ded urinary cytology has proven useful in cancer de-
tection and surveillance, past attempts at detecting PCa
cells in voided urine by traditional cytology have been
impeded by undesirably low sensitivities but high speci-
ficities [3-5]. The low sensitivity was presumably attrib-
uted to the scant number of prostate cells present in the
voided urine and the difficulty in differentiating the ma-
lignant prostatic cells from the other shed cells and deb-
ris. Thus, based on recent technological advancements,
we revisited the cytology-based approach to PCa detec-
tion in voided urine samples and investigated the use of
photodynamic diagnosis (PDD). For example, in bladder
cancer, several investigators have used photodynamic
agents such as 5-aminolevulinic acid (5-ALA) to induce
protoporphyrin IX (PPIX) accumulation in malignant
tissue, which then enables it to be differentiated from
benign tissue [6-9]. In the heme biosynthetic pathway,
5-ALA is a precursor in the heme biosynthesis pathway
and is metabolized to fluorescent PPIX before being
converted to photoinactive heme. PPIX, which tempor-
arily accumulates in the cancer cells after exogenous ap-
plication of 5-ALA, is the endogenous photosensitizer
needed for PDD [10]. Selective PPIX accumulation in
malignant tissue provides an intense color contrast be-
tween the red fluorescence of malignant lesions and the
nonfluorescence of normal tissue.
Previously, Zaak et al. reported the results of a small
feasibility study (n = 18), in which prostate tissue samples
were analyzed after exposure to 5-ALA for the presence
of prostate tumor(s). Briefly, prostate tissue samples from
16 patients who had undergone 5-ALA fluorescence mi-
croscopy revealed selective PPIX accumulation in the PCa
cells, and only weak PPIX fluorescence could be detected
in the benign epithelial cells. The two patients who were
not treated with 5-ALA revealed no PPIX fluorescence
within the prostate [11]. In this study, our aim was differ-
ent from those of previous investigators. We evaluated theTable 1 Characteristic of the study population
Males with positive biopsy (n = 81) Male
Median (range) Medi
Age (years) 72 (51-86) 67 (5
PSA (ng/ml) 9.7 (3.8-690) 7.4 (1
Free PSA (ng/ml) 1.5 (0.46-95) 1.2 (0
%fPSA (%) 15 (3-38) 17 (2
PV (cm3) 28.7 (11.5-95.2) 34.0 (
TZV (cm3) 13.3 (3.7-45) 16.9 (
PSAD (ng/ml/cm3) 0.39 (0.07-46.6) 0.20 (
Abbreviation: SD standard deviation, PSA prostate-specific antigen, %fPSA percent-frfeasibility and clinical utility of PDD for PCa by using
5-ALA-induced PPIX to examine shed PCa cells in
voided urine samples. The use of a fluorescence bio-
marker for the diagnosis of cancers is an intriguing




After receiving approval from the Nara Medical University
Hospital Institutional Review Board, 138 patients with an
abnormal DRE and/or abnormal PSA levels were recruited
between April 2009 and December 2010. All patients pro-
vided written informed consent and were subsequently
enrolled in this prospective feasibility study. Patients with
a past history of urothelial carcinoma were not eligible for
this study. For all the patients, before transrectal ultra-
sound needle-guided biopsy of the prostate, an “attentive”
(approximately 30 s) DRE was performed, and the first
50 ml of voided urine was collected. Thereafter, the pa-
tients underwent prostate needle biopsies at Nara Medical
University Hospital. Biopsies were performed by adjusting
the number of cores sampled (6–12) according to the age
of the patient and the prostatic volume. The medical re-
cords of our patients were reviewed for demographics,
clinical, and pathological information (e.g., tumor grade,
Gleason score, and tumor stage) as well as outcome. The
clinicopathological characteristics of this cohort are listed
in Table 1. All voided urine specimens were stored at 4°C
until processed, which typically occurred within 2 h of
collection.
Sample preparations and 5-ALA treatment
Urine specimens were centrifuged at 800 g for 5 min.
The supernatant was decanted, and the pellets were sus-
pended in phosphate-buffered saline (PBS) buffer, from
which two samples were collected. One sample was trea-
ted with 1-mM 5-ALA (Sigma-Aldrich Co. Saint Louis,
MO, USA), diluted with PBS, and then incubated at
37°C for 2 h. The solution was centrifuged at 5000 gs with negative biopsy (n = 57) Total (n = 138)
an (range) p-value Median (range)
5-81) 0.002 70 (51-86)
.4-24.1) 0.002 8.3 (1.4-690)
.15-3.3) 0.008 1.4 (0.15-95)
-39) 0.679 15 (3-39)
16.2-111) 0.002 30.4 (11.5-111)
2.9-78) 0.04 15.2 (2.9-78)
0.06-1.0) <0.001 0.27 (0.06-46.6)
ee PSA, PV prostate volume, TZV transition zone volume, PSAD PSA density.
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http://www.biomedcentral.com/1471-2490/14/59for 5 min, the supernatant was decanted, and 60 μl of
PBS was added to suspend the cells. Next, the cells were
applied to a charged-surface microscope slide (Figure 1).
The second aliquot of shed cells within the urine was
similarly processed, except that it was not treated with
5-ALA. Furthermore, a minute amount of material was
removed from the second aliquot in which RNA was
extracted from the cells by using the RNeasy Mini kit
(Qiagen, Hilden, Germany) as per the manufacturer’sPBS
Figure 1 Workflow of the procedure and representative PPIX–PDD st
revolutions per minute; PBS, phosphate buffered saline.instructions. A High-Capacity cDNA Reverse Transcrip-
tion kit (Life Technologies, Palo Alto, CA) was used for
the conversion cDNA. Primer sets for PSA (fp- 5′ TGAC
CAAGTTCATGCTGTGT3′ and rp- 5′ TCCTTGGAGG
CCATGTGGGCCAT 3′) were used to perform quantita-
tive reverse transcription polymerase chain reaction (RT-
PCR). Further, the relative fold changes in mRNA levels
were calculated after normalization to glyceraldehyde
3-phosphate dehydrogenase (GAPDH).aining. DRE, digital rectal examination; ALA, aminolevulinic acid; RPM,





PSAD (cut-off 0.15) 93.8% 29.8%
%fPSA (cut-off 20%) 78.7% 26.3%
PSA (cut-off 4ng/ml) 60.1% 50.0%
TRUS 34.6% 96.5%
Abbreviation: ALA aminolevulinic acid, DRE digital rectal examination, TRUS
transrectal ultrasinography, PSAD PSA density, %fPSA percent free PSA.
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http://www.biomedcentral.com/1471-2490/14/59Photodynamic detection of PPIX in shed prostate cells
5-ALA-treated (and 5-ALA-untreated) urine cytospin
slides were investigated for PPIX fluorescence at 100×
magnification by fluorescent microscopy with the ap-
propriate fluorescence filter sets (excitation filter, 380–
420 nm; emission filter, 590 nm; Nikon Eclipse 400;
Nikon Instruments Inc., Melville, NY, USA). The slides
were evaluated for the following: (i) PPIX positivity,
presence of cells demonstrating simultaneous fluores-
cence of PPIX and (ii) PPIX negativity, lack of cells dem-
onstrating fluorescence.
Statistical analysis
The Mann–Whitney test was used to analyze the dif-
ferences between the patients with or without PCa. We
used the Chi-square test for trend to analyze whether
the incidence of PPIX–PDD positivity was associated
with cancer, PSA, Gleason score, and tumor stage. Mul-
tivariate logistic regression analysis was used to evaluate
the demographic features, key clinical features [e.g., DRE,
total PSA,%fPSA, PSA density (PSAD), and transrectal
ultrasonography (TRUS)], and the PPIX–PDD results in
order to determine their ability to independently predict
PCa on prostate biopsy. Differences were considered sta-
tistically significant at p values <0.05.
Results
In this study, 81/138 (58.7%) patients revealed PCa on
needle biopsy (Table 1). The median age of the patients
without PCa was 67 (range 55–81) years, and the median
age of patients with PCa was 72 (range 51–86) years (p =
0.002). The median PSA of the patients without PCa was
7.4 (range 1.4-24.1) ng/ml, and the median PSA of the pa-
tients with PCa was 9.7 (range 3.8-690) ng/ml (p = 0.002).
Furthermore, the median free PSA (1.5 vs. 1.2 ng/ml, p =
0.008) and PSAD (0.39 vs. 0.20 ng/ml/cm3, p < 0.001)
values differed significantly between the patients with and
without PCa, respectively. In addition, prostate volume
(34.0 vs. 28.7 ml, p = 0.002) and transition zone volume
(16.9 vs. 13.3 ml, p = 0.04) were significantly higher in the
patients with PCa than in those without PCa.
The typical fluorescence of urine sediments placed on
a cytospin slide from a patient with PCa was compared
to its corresponding unstained urine sediments (Figure 1).
These cells were found to express PSA by RT-PCR
and were thus considered to be prostate cells (data not
shown). The human prostate cancer cell line PC-3 was
used as a positive control. Table 2 compares the PPIX–
PDD results with the other clinical parameters (e.g., DRE,
PSA,%fPSA, PSAD, and prostate volume) associated with
PCa detection. Of the 81 patients with biopsy-proven
PCa, 60 were determined positive for PPIX–PDD (sensi-
tivity: 74.1%). PPIX–PDD was more sensitive compared
with DRE and TRUS and more specific compared withPSA and PSAD. Although 57 patients did not harbor PCa
by conventional diagnostic procedures, 17 of these at-risk
patients were determined positive for PPIX–PDD (specifi-
city: 70.2%). These patients have been under close surveil-
lance to evaluate if their positive PPIX–PDD results will
convert to clinical PCa.
The diagnostic accuracy of PPIX–PDD in the males
with positive biopsy at different total PSA levels was 2/2
(100%) patients for PSA levels within 0–4 ng/ml, 28/39
(71.8%) for PSA levels within 4–10 ng/ml, 11/15 (73.3%)
for PSA levels within 10–20 ng/ml, and 19/25 (76.0%)
for PSA levels >20 ng/ml. The diagnostic accuracy at dif-
ferent tumor stages was 34/45 (75.6%) for tumor stage
cT1, 22/32 (68.8%) for cT2, and 4/4 (100%) for cT3. The
incidence of PPIX–PDD positivity did not increase with
increase in the total PSA levels (p = 0.25) and tumor
stage (p = 0.87).Furthermore, the diagnostic accuracy of
PPIX–PDD in the males with positive biopsies was 15/24
(62.5%) for Gleason score (GS) 6, 26/34 (76.4%) for GS 7,
and 19/23 (82.6%) for GS 8–10.The incidence of PPIX–
PDD positivity increased with increasing GS, but the in-
crease was not significant (p = 0.11) (Table 3).
In addition, on multivariate analysis, we evaluated the
demographic features, key clinical features (e.g., DRE,
total PSA,%fPSA, PSAD, and TRUS), and PPIX–PDD re-
sults to determine their ability to independently predict
PCa on prostate biopsy (Table 4). Multivariate analysis
indicated that ALA (HR, 8.00; 95% CI, 2.50–25.59; p <
0.001) and PSAD (HR, 28.43; 95% CI, 8.12–99.58; p <
0.001) were independent diagnostic factors for PCa.
Discussion
In this study, we demonstrated the feasibility of PPIX–
PDD and 5- ALA in noninvasive detection of PCa cells
extracorporeally in voided urine sediments. The use of
voided urine samples in an attempt to diagnosis PCa is
gaining widespread attention. For example, investigators
are using RT-PCR to identify the prostate cancer antigen
3 (PCA-3) [12] and glutathione S-transferase P112 gene
[13] in voided urine samples. Particularly, the sensitivity
Table 3 Diagnostic accuracy of PDD according to total








0-4 2 2 100%
4-10 39 28 71.8%
10-20 15 11 73.3%
20- 25 19 76.0% 0.25
Gleason score
6 24 15 62.5%
7 34 26 76.4%
8-10 23 19 82.6 0.11
Clinical stage
cT1 45 34 75.6%
cT2 32 22 68.8%
cT3 4 4 100%
cT4 - - - 0.87
*Chi-square test for trend.
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and 74%, respectively, for the entire cohort and 53% and
71%, respectively, for PSA within 4–10 ng/ml. In the
present study, the sensitivity and specificity of PPIX–
PDD were 74.1% and 70.2% in the entire cohort and
70.0% and 67.6% in the gray zone cases, which were su-
perior to those reported for PCA-3. Interestingly, the
positivity rate of PPIX–PDD did not increase with in-
creasing total PSA or tumor stage. However, the posi-
tivity rate of PPIX–PDD did increase with increasing
Gleason score though a non-significant trend (p = 0.11)
was noted. These results showed a possibility that PCa
detection with PPIX–PDD identified more clinically sig-
nificant PCa compared with PCa detected by other
reported methods. Stummer et al. reported that the fluo-
rescence intensity of glioma by PPIX–PDD was associ-
ated with cellular density, tumor proliferation, and tumor
angiogenesis [14]; these results supported our resultsTable 4 Univariate and multivariate analysis of factors to pre
Univariate analysis
OR 95% CI
ALA (positive/negative) 6.72 3.16-14.29
DRE (abnormal/normal) 8.00 2.89-22.15
PSAD (>0.15/<0.15) 34.20 11.63-100.54
% fPSA (>20%/<20%) 1.57 0.71-3.53
PSA (>20/>10, <20/<10) 2.37 1.43-3.95
TRUS (abnormal/normal) 13.50 3.06-59.66
Abbreviation: OR odds ratio, ALA aminolevulinic acid, DRE digital rectal examination,indicating that PPIX–PDD detected more aggressive
clinically relevant cancers.
Although no reports regarding fluorescent cytology of
shed PCa cells were found in the literature, several re-
ports from the bladder cancer literature are available
[15-17]; in these reports, voided urine after intravesical
5-ALA instillation was evaluated. Inoue et al. reported
that regardless of the 5-ALA administration route (intra-
vesical or oral), exposure to 5-ALA was well tolerated
with only cystitis symptoms being reported [18]. Hence,
in this extracorporeal model, shed prostate cells rather
than patients were treated with 5-ALA.
Although the findings in the present study were quite
compelling, the study had some limitations. First, we ob-
tained limited pathological data on the patients with
positive PPIX–PDD results and positive prostate biopsy
results who proceeded to undergo radical prostatectomy.
Second, with limited follow-up (mean follow-up, 27
months), we must cautiously interpret the false-positive
PPIX–PDD results. It is possible that over time, these
prostate biopsies will become positive. In this cohort,
only 4 false positive patients had been performed re-
peated prostate needle biopsies after this study. 2 pa-
tients of them were diagnosed as prostate cancer. These
false positive patients may need strict PSA follow-up or
a saturation biopsy. Third, we didn’t perform RT-PCR
for every patient. We demonstrated RT-PCR in the first
twenty patients. Then we evaluated the expression of
PSA. We could confirm the existence of cells from pros-
tate by that. In addition, these false-positive results may
be attributed to autofluorescence. Tauber et al. reported
that some biological materials had autofluorescence. To
address this issue, the authors used bleaching fluores-
cence; however, the specificity of bleaching fluorescence
was comparatively low [16]. In our study, we were able
to subjectively estimate autofluorescence by examining
the slide not treated with 5-ALA from each patient. Fur-
thermore, cytological examinations are known to present
interobserver variability. In the future, we hope to de-
velop a more objective spectrophotometric method to
quantify the intensity of PPIX fluorescence.dict PCa on prostate biopsy
Multivariate analysis
p-value OR 95% CI p-value
<0.001 8.00 2.50-25.59 <0.001
<0.001 1.77 0.32-9.38 0.52
<0.001 28.43 8.12-99.58 <0.001
0.27
0.001 1.97 0.81-4.80 0.14
0.001 7.35 0.52-104.58 0.14
PSAD PSA density, %fPSA percent free PSA, TRUS transrectal uktrasonography.
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To our knowledge, this is the first successful demonstra-
tion of PPIX in urine sediments treated with 5-ALA for
detection of PCa in a noninvasive yet highly sensitive
manner. The incidence of PPIX–PDD positivity increased
with increasing Gleason score though a non-siginificant
trend (p = 0.11) was noted. Further studies are warranted
to determine the role of PPIX–PPD for PCa detection.
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